Literature DB >> 6400754

The calcium channel blockers: pharmacology and clinical applications.

H F Mizgala1.   

Abstract

The calcium channel blockers provide an exciting and effective new therapeutic tool in the management of ischaemic cardiac syndromes and may prove popular and effective in the treatment of a variety of other disorders. They have provided a new approach to treatment and have added new insights into the pathogenesis of ischaemic cardiac syndromes. Their introduction into clinical practice has been swift and many of our concepts regarding their pharmacologic activities in man remain based on theoretic considerations. Their expanding clinical use and further comparative studies will undoubtedly provide further information in regard to indications, adverse effects, drug interaction and long-term safety. Particular caution is advised when they are combined with certain antiarrhythmic agents, digitalis and particularly beta adrenergic blocking agents. Little is known about their interaction with various general anaesthetic agents and for this reason particular vigilance is required as more patients receiving these agents are admitted for surgical procedures.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6400754     DOI: 10.1007/BF03009971

Source DB:  PubMed          Journal:  Can Anaesth Soc J        ISSN: 0008-2856


  10 in total

1.  Verapamil in the treatment of hypertrophic cardiomyopathy.

Authors:  D R Rosing; S E Epstein
Journal:  Ann Intern Med       Date:  1982-05       Impact factor: 25.391

2.  A comparative study of calcium-ion antagonists in patients with variant angina.

Authors:  D D Waters; P Théroux; J Szlachcic; H F Mizgala
Journal:  Clin Invest Med       Date:  1980       Impact factor: 0.825

Review 3.  Mechanism of action of calcium-channel-blocking agents.

Authors:  E Braunwald
Journal:  N Engl J Med       Date:  1982-12-23       Impact factor: 91.245

4.  Nifedipine and beta-blockade as a cause of cardiac failure.

Authors:  R H Robson; M C Vishwanath
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-09

Review 5.  Hemodynamic and clinical effects of combined verapamil and propranolol therapy in angina pectoris.

Authors:  M Packer; M B Leon; R O Bonow; J Kieval; D R Rosing; V B Subramanian
Journal:  Am J Cardiol       Date:  1982-10       Impact factor: 2.778

Review 6.  Verapamil and digoxin: their respective effects on atrial fibrillation and their interaction.

Authors:  H O Klein; E Kaplinsky
Journal:  Am J Cardiol       Date:  1982-10       Impact factor: 2.778

7.  Halothane depression of myocardial slow action potentials.

Authors:  C Lynch; S Vogel; N Sperelakis
Journal:  Anesthesiology       Date:  1981-10       Impact factor: 7.892

Review 8.  Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiologic effects.

Authors:  E M Antman; P H Stone; J E Muller; E Braunwald
Journal:  Ann Intern Med       Date:  1980-12       Impact factor: 25.391

Review 9.  Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem.

Authors:  P D Henry
Journal:  Am J Cardiol       Date:  1980-12-01       Impact factor: 2.778

10.  Rationale for the choice of calcium antagonists in chronic stable angina. An objective double-blind placebo-controlled comparison of nifedipine and verapamil.

Authors:  V B Subramanian; M J Bowles; N S Khurmi; A B Davies; E B Raftery
Journal:  Am J Cardiol       Date:  1982-11       Impact factor: 2.778

  10 in total
  3 in total

1.  Modern and Evolving Understanding of Cerebral Perfusion and Autoregulation.

Authors:  Nathaniel H Greene; Lorri A Lee
Journal:  Adv Anesth       Date:  2012

Review 2.  Anaesthetic implications of calcium channel blockers.

Authors:  L C Jenkins; P J Scoates
Journal:  Can Anaesth Soc J       Date:  1985-07

3.  Hypotensive actions of diltiazem and nitroprusside compared during fentanyl anaesthesia for total hip arthroplasty.

Authors:  J M Bernard; M Pinaud; S Carteau; C Hubert; R Souron
Journal:  Can Anaesth Soc J       Date:  1986-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.